Precision Medicine in Castration-Resistant Prostate Cancer
Korean Journal of Urological Oncology
;
: 97-102, 2018.
Artigo
em Coreano
| WPRIM
| ID: wpr-741483
ABSTRACT
Prostate cancer is usually managed by androgen deprivation therapy after failure of primary treatment. However, such therapies are only temporarily effective in prostate cancer patients, and the most patients experience the progression to castration-resistant prostate cancer (CRPC). Docetaxel chemotherapy is conventional effective treatment for CRPC but has many adverse effects. In CRPC patients, treatment decisions were not typically base on the recognitions of inter-individual differences. Therefore, there are growing interests for precision medicine in CRPC. In this review, we summarized the precision medicine such as candidate target genes and potential therapies in CRPC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Próstata
/
Neoplasias da Próstata
/
Tratamento Farmacológico
/
Medicina de Precisão
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Urological Oncology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS